Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy – Phase II
2016-004043-36Phase 2Completed
- Sponsor
- Uppsala University
- Start
- Jan 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-CD19 3rd generation CAR T cells in mature B-cell lymphoma, B cell acute lymphoblastic leukemia (B-ALL) and Hodgkin lymphoma (HL), sponsored by Uppsala University. Primary endpoint: Safety profile. Started Jan 2017; status: completed.
02
Drugs
anti-CD19 3rd generation CAR T cells
03
Conditions
mature B-cell lymphomaB cell acute lymphoblastic leukemia (B-ALL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2016-004043-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004043-36.